Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18670803 | STABILIZED HEMAGGLUTININ (HA) TRIMERS AS INFLUENZA VACCINE ANTIGENS | May 2024 | August 2024 | Allow | 3 | 0 | 0 | No | No |
| 18590312 | RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18444663 | Composition for Treating or Preventing Insulin Resistance | February 2024 | September 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18412485 | ENTEROVIRUS MULTI-ANTIGEN EPITOPE FUSION PROTEIN, GENE, VACCINE, AND PREPARATION METHOD THEREOF | January 2024 | June 2024 | Allow | 5 | 0 | 0 | No | No |
| 18411284 | PREFUSION-STABILIZED HMPV F PROTEINS | January 2024 | April 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18533042 | Nant COVID Vaccine Cross Reactivity | December 2023 | February 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18518304 | METHODS AND PRODUCTS FOR GENETIC ENGINEERING | November 2023 | May 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18513970 | ANALYTICAL ULTRACENTRIFUGATION FOR CHARACTERIZATION OF RECOMBINANT VIRAL PARTICLES | November 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18512730 | SELF-REPLICATING RNA AND USES THEREOF | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18388792 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | November 2023 | February 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18506853 | ANALYTICAL ULTRACENTRIFUGATION FOR CHARACTERIZATION OF RECOMBINANT VIRAL PARTICLES | November 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18501578 | CHIMERIC INFLUENZA VACCINES | November 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18477695 | UNIVERSAL INFLUENZA VACCINE | September 2023 | May 2024 | Allow | 8 | 1 | 0 | No | No |
| 18473720 | Mutated Glycoprotein of Vesicular Stomatitis Virus | September 2023 | February 2024 | Allow | 5 | 0 | 0 | No | No |
| 18465353 | NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS | September 2023 | March 2024 | Allow | 6 | 1 | 0 | No | No |
| 18465414 | NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS | September 2023 | March 2024 | Allow | 6 | 0 | 0 | No | No |
| 18464786 | PREFUSION RSV F PROTEINS AND THEIR USE | September 2023 | December 2023 | Allow | 3 | 0 | 0 | No | No |
| 18463276 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | September 2023 | December 2023 | Allow | 3 | 1 | 0 | No | No |
| 18034141 | VACCINE COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-CORONAVIRUS-2 INFECTION | August 2023 | June 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18458628 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | August 2023 | June 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18237913 | HPV Therapeutic Nucleic Acid Vaccine | August 2023 | October 2023 | Allow | 2 | 0 | 0 | No | No |
| 18454526 | LAMP Constructs | August 2023 | June 2024 | Allow | 9 | 1 | 1 | No | No |
| 18452741 | VACCINE BOOSTER COMPOSITIONS FOR RESPIRATORY VIRAL DISEASES | August 2023 | August 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18260497 | SARS-CoV-2 mRNA Vaccine and Preparation Method and Use Thereof | August 2023 | January 2024 | Allow | 6 | 0 | 0 | No | No |
| 18365869 | ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE | August 2023 | March 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18228700 | LIPID DELIVERY SYSTEM AND VIRUS-LIKE STRUCTURE (VLS) VACCINE CONSTRUCTED THEREFROM | August 2023 | January 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18353375 | ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES | July 2023 | June 2024 | Allow | 11 | 1 | 2 | No | No |
| 18351065 | NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS | July 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18350273 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND USE FOR INHIBITING AGIOGENESIS | July 2023 | September 2023 | Abandon | 2 | 0 | 0 | No | No |
| 18348910 | PRODUCTION OF LYTIC PHAGES | July 2023 | January 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18342949 | Trimer Stabilizing HIV Envelope Protein Mutations | June 2023 | April 2024 | Allow | 9 | 0 | 0 | No | No |
| 18341590 | CORONAVIRUS VACCINE | June 2023 | October 2023 | Allow | 4 | 0 | 0 | No | No |
| 18268890 | NOVEL ADENOVIRAL VECTOR NOT INCLUDING REPLICATION COMPETENT ADENOVIRUS, AND USE THEREOF | June 2023 | June 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18336439 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME | June 2023 | July 2024 | Allow | 13 | 0 | 0 | No | No |
| 18335879 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | June 2023 | June 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18335869 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | June 2023 | April 2024 | Allow | 10 | 0 | 0 | No | No |
| 18335876 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | June 2023 | April 2024 | Allow | 10 | 0 | 0 | No | No |
| 18335893 | ANTIGENIC EPSTEIN BARR VIRUS POLYPEPTIDES | June 2023 | March 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18334497 | ZIKA VIRUS VACCINE | June 2023 | July 2024 | Allow | 13 | 0 | 0 | No | No |
| 18334022 | METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES | June 2023 | February 2024 | Allow | 8 | 1 | 1 | No | No |
| 18330167 | ENGINEERED RED BLOOD CELLS HAVING RARE ANTIGEN PHENOTYPES | June 2023 | June 2024 | Allow | 12 | 0 | 0 | No | No |
| 18328528 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | June 2023 | August 2023 | Allow | 3 | 0 | 0 | No | No |
| 18328557 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | June 2023 | August 2023 | Allow | 2 | 0 | 0 | No | No |
| 18328544 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | June 2023 | February 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18202596 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | May 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18323135 | CAPSID VARIANTS AND METHODS OF USING THE SAME | May 2023 | June 2024 | Allow | 13 | 1 | 2 | Yes | No |
| 18038107 | DEVELOPING LATERAL FLOW IMMUNOCHROMATOGRAPHY (LFIA) PEPTIDE-BASED TEST STRIPS FOR RAPID DETECTION OF ANTIGENS AND ANTIBODIES AGAINST SPECIFIC ANTIGENS | May 2023 | January 2024 | Allow | 8 | 0 | 0 | No | No |
| 18319918 | PRODUCTION BACTERIAL CELLS AND USE THEREOF IN PRODUCTION METHODS | May 2023 | November 2023 | Allow | 6 | 1 | 0 | No | No |
| 18318996 | INDIRECT ENZYME-LINKED IMMUNOSORBENT ASSAY DETECTION KIT BASED ON P30 PROTEIN AND P22 PROTEIN OF AFRICAN SWINE FEVER VIRUS | May 2023 | September 2024 | Abandon | 16 | 2 | 0 | No | No |
| 18318093 | OIL-BASED ADJUVANTS | May 2023 | June 2024 | Allow | 13 | 0 | 0 | No | No |
| 18316191 | MODIFIED VIRAL PARTICLES FOR GENE THERAPY | May 2023 | December 2023 | Allow | 8 | 1 | 0 | No | No |
| 18314052 | STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF | May 2023 | December 2023 | Allow | 7 | 0 | 0 | No | No |
| 18313017 | ADJUVANTED VACCINES CONTAINING MODIFIED S1 SPIKE PROTEIN OF SARS-COV-2 VARIANT C.1.2 FOR SUBCUTANEOUS ADMINISTRATION AND METHODS OF USE | May 2023 | October 2023 | Allow | 5 | 0 | 0 | No | No |
| 18312072 | EBIV NUCLEIC ACID COMPOSITION AND APPLICATION THEREOF | May 2023 | March 2024 | Allow | 10 | 0 | 0 | No | No |
| 18308583 | PRE-FUSION RSV F ANTIGENS | April 2023 | March 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18308590 | METHODS OF PREDICTING ANCESTRAL VIRUS SEQUENCES AND USES THEREOF | April 2023 | June 2024 | Allow | 14 | 0 | 1 | No | No |
| 18301818 | Inducible AAV REP genes | April 2023 | March 2024 | Allow | 11 | 1 | 0 | No | No |
| 18300124 | COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT | April 2023 | September 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18296771 | PREFUSION-STABILIZED HMPV F PROTEINS | April 2023 | December 2023 | Allow | 8 | 1 | 0 | No | No |
| 18192274 | METHOD OF COMPACT PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | March 2023 | May 2024 | Allow | 13 | 0 | 0 | No | No |
| 18126140 | PROTEIN-BASED NANOPARTICLE VACCINE FOR METAPNEUMOVIRUS | March 2023 | August 2023 | Allow | 5 | 0 | 0 | No | No |
| 18125069 | Systems and Methods for Targeted Mass Inoculation | March 2023 | December 2023 | Allow | 8 | 1 | 1 | No | No |
| 18188176 | ANALYTICAL ULTRACENTRIFUGATION FOR CHARACTERIZATION OF RECOMBINANT VIRAL PARTICLES | March 2023 | May 2024 | Allow | 13 | 1 | 0 | No | No |
| 18186874 | CORONAVIRUS DISEASE (COVID-19) VACCINE | March 2023 | January 2024 | Allow | 10 | 1 | 1 | No | No |
| 18185898 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18186064 | POLYOMAVIRUS NEUTRALIZING ANTIBODIES | March 2023 | April 2024 | Allow | 13 | 0 | 0 | No | No |
| 18185153 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18119973 | ADJUVANT AND VACCINE CONTAINING ADJUVANT | March 2023 | August 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18179474 | IMMUNOGENIC COMPOSITION AND VACCINE FOR GENERATING AN IMMUNE RESPONSE TO NOROVIRUS | March 2023 | September 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18179352 | CORONAVIRUS VACCINE | March 2023 | September 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18179339 | CORONAVIRUS VACCINE | March 2023 | November 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18178638 | ZIKA VIRUS VACCINE | March 2023 | June 2023 | Allow | 3 | 0 | 0 | No | No |
| 18177413 | METHOD FOR ADAPTING INFLUENZA VIRUSES TO VERO CELLS | March 2023 | May 2024 | Allow | 14 | 0 | 0 | No | No |
| 18115066 | CANCER IMMUNOTHERAPY USING VIRUS PARTICLES | February 2023 | April 2024 | Allow | 14 | 1 | 0 | No | No |
| 18174939 | CORONAVIRUS: EARLY DETECTION AND TREATMENT | February 2023 | September 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18043017 | METHOD FOR DETERMINING SUSCEPTIBILITY TO SARS-COV-2 INFECTION | February 2023 | February 2024 | Allow | 12 | 1 | 0 | No | No |
| 18173006 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | February 2023 | September 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18172836 | Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof | February 2023 | April 2024 | Allow | 13 | 0 | 1 | Yes | No |
| 18110734 | ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST | February 2023 | March 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18169440 | STEROID ACID-BASED IMMUNOGEN ENHANCERS | February 2023 | April 2024 | Allow | 14 | 1 | 0 | No | No |
| 18168396 | SUSPENSION SYSTEM FOR ADENO ASSOCIATED VIRUS PRODUCTION | February 2023 | May 2024 | Allow | 15 | 0 | 0 | No | No |
| 18108248 | COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS | February 2023 | January 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18165762 | Coxsackievirus 83 Vaccine | February 2023 | October 2024 | Abandon | 20 | 4 | 0 | Yes | No |
| 18165804 | MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS COMPRISING MODIFIED NOROVIRUS VP1 PROTEINS | February 2023 | April 2024 | Allow | 14 | 0 | 0 | No | No |
| 18105864 | Method for Pathogen Identification | February 2023 | October 2023 | Allow | 8 | 1 | 0 | No | No |
| 18162530 | RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 1 EXPRESSING A CHIMERIC RSV/HPIV1 F PROTEIN AND USES THEREOF | January 2023 | February 2024 | Allow | 12 | 1 | 0 | No | No |
| 18103214 | SMALLPOX VACCINE FOR CANCER TREATMENT | January 2023 | March 2024 | Allow | 13 | 1 | 1 | No | No |
| 18103343 | ENGINEERED INFLUENZA POLYNUCLEOTIDES, VIRUSES, VACCINES AND METHODS OF MAKING AND USING THE SAME | January 2023 | June 2024 | Allow | 17 | 1 | 1 | No | No |
| 18159827 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | January 2023 | April 2024 | Allow | 14 | 0 | 0 | No | No |
| 18158800 | Combination Immunotherapy Compositions Against Cancer and Methods | January 2023 | May 2024 | Allow | 16 | 0 | 0 | No | No |
| 18100732 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | January 2023 | July 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18157534 | NUCLEOTIDE SEQUENCE EXPRESSING AN EXOSOME-ANCHORING PROTEIN FOR USE AS VACCINE | January 2023 | August 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18099044 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | January 2023 | February 2024 | Allow | 12 | 0 | 0 | No | No |
| 18099035 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | January 2023 | March 2024 | Allow | 14 | 0 | 0 | No | No |
| 18156982 | CORONAVIRUS VACCINE COMPRISING A MOSAIC PROTEIN | January 2023 | February 2024 | Allow | 12 | 1 | 1 | No | No |
| 18097004 | METHODS FOR DETECTING NOROVIRUS | January 2023 | April 2024 | Allow | 15 | 0 | 0 | No | No |
| 18153233 | METHODS OF TREATING A LATENT HIV-1 INFECTION USING NON-CODING DEOXYRIBONUCLEIC ACIDS | January 2023 | July 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18151803 | CLOSED-ENDED, LINEAR, DUPLEX ADENOASSOCIATED VIRUS DNA, AND USES THEREOF | January 2023 | July 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18152077 | BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS | January 2023 | February 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18150957 | MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITY | January 2023 | February 2024 | Allow | 13 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1648.
With a 29.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1648 is part of Group 1640 in Technology Center 1600. This art unit has examined 13,742 patent applications in our dataset, with an overall allowance rate of 58.2%. Applications typically reach final disposition in approximately 30 months.
Art Unit 1648's allowance rate of 58.2% places it in the 12% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1648 receive an average of 1.90 office actions before reaching final disposition (in the 57% percentile). The median prosecution time is 30 months (in the 41% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.